

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 June 2024 (13.06.2024)



(10) International Publication Number
WO 2024/123570 A1

(51) International Patent Classification:

C07F 15/02 (2006.01) *A61P 35/04* (2006.01)
A61K 33/00 (2006.01) *B01J 31/22* (2006.01)
A61K 33/24 (2019.01) *C07C 51/41* (2006.01)
A61K 33/26 (2006.01) *A61P 35/00* (2006.01)

No. 9, Liren St., Zhonghe Dist., New Taipei City, 235 (TW).
TSENG, Chang-Yuan; No. 128, Fenglin 2nd Rd., Wande
Village, Sanxing Township, Yilan County (TW). **SHEU,**
Jenn-Line; 14F., No. 13, Lianfa St., Zhubei City, Hsunchu
County (TW).

(21) International Application Number:

PCT/US2023/081481

(74) Agent: **KAO, Laurence**; OPES IP CONSULTING CO.,
LTD., 4F., No. 205, Sec. 1, Fuxing S. Rd., Daan Dist., Taipei
City, 10666 (TW).

(22) International Filing Date:

29 November 2023 (29.11.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


63/431,320 09 December 2022 (09.12.2022) US

(71) Applicant: **HUEIYUAN BIOTECH LLC** [US/US]; 1330
Avenue of the Americas Ste 23A, New York, NY 10019
(US).

(72) Inventors: **PIEN, Hsueh-Fa**; 5F., No. 9, Liren St., Zhonghe
Dist., New Taipei City, 235 (TW). **PIEN, Chia-Hsuan**; 5F.,

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: COORDINATION COMPOUND, COMPOSITIONS, AND USES THEREOF FOR TREATING CANCERS



(57) Abstract: Provided is a coordination compound represented by formula (I). Also provided is a pharmaceutical composition that can be used to treat cancers, including the coordination compound of formula (I) and a pharmaceutically acceptable carrier. Also provided are applications of the coordination compound in inhibiting cancer cell survival or proliferation, inhibiting cancer cell migration or invasion, and treating cancerous tumors in a subject in need.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*